Fish oil supplementation and inflammatory response during neoadjuvant chemoradiation for rectal cancer: Results from a prospective, randomized, controlled trial.

Silva, Juliana de Aguiar Pastore; Silva, Mariane Messias Reis Lima; Mello, Celso Lopes; Begnami, Maria D.; Silva, Maria Letícia Gobo; Aguiar, Samuel

doi:10.1200/jco.2018.36.15_suppl.3605

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A double-blind, placebo-controlled RCT (n=140) in patients with CRC receiving chemotherapy evaluated the use of a strain-specific probiotic, (microbial cell preparation, Hexbio) and 2 g/day of O3FA (700 mg/day EPA and DHA) over 8 weeks, reporting an improvement in global health status (p<0.001) and chemotherapy-related adverse events (diarrhoea, anorexia)—in addition to a reduction in IL-6 (p=0.002), but no difference in TNF-α or CRP levels 115. However, a statistically significant reduction in the Glasgow Prognostic Score (GPS) (an inflammation-based cancer prognostic marker composed of CRP and albumin) was demonstrated in an RCT of 2.4 g/day O3FA capsules in patients with local advanced rectal cancer receiving neoadjuvant radiotherapy (published abstract only) 116…”

Section: Do Omega-3 Polyunsaturated Fatty Acids Alter Post-diagnosis ...mentioning

confidence: 99%

Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer

Aldoori

Cockbain

Toogood

2022

Gut

View full text Add to dashboard Cite

Data from experimental studies have demonstrated that marine omega-3 polyunsaturated fatty acids (O3FAs) have anti-inflammatory and anticancer properties. In the last decade, large-scale randomised controlled trials of pharmacological delivery of O3FAs and prospective cohort studies of dietary O3FA intake have continued to investigate the relationship between O3FA intake and colorectal cancer (CRC) risk and mortality. Clinical data suggest that O3FAs have differential anti-CRC activity depending on several host factors (including pretreatment blood O3FA level, ethnicity and systemic inflammatory response) and tumour characteristics (including location in the colorectum, histological phenotype (eg, conventional adenoma or serrated polyp) and molecular features (eg, microsatellite instability, cyclooxygenase expression)). Recent data also highlight the need for further investigation of the effect of O3FAs on the gut microbiota as a possible anti-CRC mechanism, when used either alone or in combination with other anti-CRC therapies. Overall, these data point towards a precision approach to using O3FAs for optimal prevention and treatment of CRC based on mechanistic understanding of host, tumour and gut microbiota factors that predict anticancer activity of O3FAs.

show abstract

Section: Do Omega-3 Polyunsaturated Fatty Acids Alter Post-diagnosis ...mentioning

confidence: 99%

Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer

Aldoori

Cockbain

Toogood

2022

Gut

View full text Add to dashboard Cite

show abstract

“…The study also showed decreased IL-6 levels but no significant difference in TNF-α or CRP levels [95]. Another RCT found that ω-3 FAs capsules significantly reduced the Glasgow Prognostic Score (GPS), a prognostic cancer marker based on inflammation composed of CRP and albumin, in patients with local advanced rectal cancer receiving neoadjuvant radiotherapy [96]. In a double-blind, placebo-controlled, randomized controlled trial, the effectiveness of ω-3 FAs in mitigating oxaliplatin-induced peripheral neurotoxicity (OXIPN) was investigated: ω-3 FA capsules (640 mg, three times daily) containing DHA (54%) and EPA (10%) reduced both the frequency and severity of OXIPN.…”

Section: ω3 Fas: An Adjunct To Chemotherapy?mentioning

confidence: 86%

Anti-Inflammatory and Immune Properties of Polyunsaturated Fatty Acids (PUFAs) and Their Impact on Colorectal Cancer (CRC) Prevention and Treatment

Tojjari,

Choucair,

Sadeghipour

et al. 2023

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains a leading cause of death from cancer worldwide, with increasing incidence in the Western world. Diet has become the focus of research as a significant risk factor for CRC occurrence, and the role of dietary polyunsaturated fatty acids (PUFAs) has become an area of interest given their potential role in modulating inflammation, particularly in the pro-carcinogenic inflammatory environment of the colon. This work reviews the main types of PUFAs, their characteristics, structure, and physiologic role. We then highlight their potential role in preventing CRC, their signaling function vis-à-vis tumorigenic signaling, and their subsequent potential role in modulating response to different treatment modalities. We review pre-clinical and clinical data and discuss their potential use as adjunct therapies to currently existing treatment modalities. Given our understanding of PUFAs’ immune and inflammation modulatory effects, we explore the possible combination of PUFAs with immune checkpoint inhibitors and other targeted therapies.

show abstract

Fish oil supplementation and inflammatory response during neoadjuvant chemoradiation for rectal cancer: Results from a prospective, randomized, controlled trial.

Cited by 2 publications

References 0 publications

Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer

Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer

Anti-Inflammatory and Immune Properties of Polyunsaturated Fatty Acids (PUFAs) and Their Impact on Colorectal Cancer (CRC) Prevention and Treatment

Contact Info

Product

Resources

About